Core Viewpoint - The inclusion of Lairosilib (GB491) in the National Medical Insurance Drug List is expected to enhance patient accessibility and accelerate commercialization, thereby boosting innovative returns for the company [1]. Group 1: Drug Inclusion - Lairosilib (GB491) has been included in the National Medical Insurance Drug List published by the National Healthcare Security Administration, effective from January 1, 2026 [1]. - This marks the first time Lairosilib (GB491) has been included in the national medical insurance drug list [1]. Group 2: Drug Description and Indications - Lairosilib (GB491) is a novel, highly selective oral CDK4/6 inhibitor, indicated for adult patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1]. - It is used in combination with aromatase inhibitors as initial endocrine therapy and with Fulvestrant for patients with disease progression after prior endocrine therapy [1]. Group 3: Impact on Patients and Market - The inclusion in the insurance list is expected to significantly improve drug accessibility for patients and reduce their financial burden [1]. - This development is anticipated to accelerate the commercialization process and market penetration of Lairosilib (GB491) [1].

Core Viewpoint - The inclusion of Lairosilib (GB491) in the National Medical Insurance Drug List is expected to enhance patient accessibility and accelerate commercialization, thereby boosting innovative returns [1] Group 1: Drug Inclusion - Lairosilib (GB491) has been included in the National Medical Insurance Drug List published by the National Healthcare Security Administration on December 7, 2025 [1] - This marks the first time Lairosilib (GB491) has been included in the national medical insurance drug list [1] - The new drug list will take effect on January 1, 2026 [1] Group 2: Drug Profile - Lairosilib (GB491) is a novel, highly selective oral CDK4/6 inhibitor indicated for adult patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1] - It is used in combination with aromatase inhibitors as initial endocrine therapy and with Fulvestrant for patients with disease progression after prior endocrine therapy [1] Group 3: Market Impact - The company believes that the inclusion of Lairosilib (GB491) in the insurance list will significantly improve patient access to the drug and reduce their financial burden [1] - This development is expected to accelerate the commercialization process and market penetration of Lairosilib (GB491) [1] - The move is anticipated to further enhance innovative returns for the company [1]

Core Viewpoint - Jiahe Biotech-B (06998.HK) announced that its drug Lairosili (GB491) has been included in the National Medical Insurance Drug List (2025) released by the National Healthcare Security Administration on December 7, 2025, marking its first inclusion in the national medical insurance drug list [1] Group 1 - Lairosili (GB491) is a novel, highly selective oral CDK4/6 inhibitor indicated for adult patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1] - The new National Medical Insurance Drug List will take effect on January 1, 2026 [1] - The inclusion of Lairosili (GB491) in the medical insurance list is expected to significantly enhance patient accessibility to the drug and reduce their financial burden [1] Group 2 - The company believes that the inclusion in the insurance list will accelerate the commercialization process and market penetration of Lairosili (GB491), further boosting innovation returns [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告由嘉和生物藥業（開曼）控股有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以知會本公司股東及潛在投資者有關本集團最新業務更新。 （股份代號：6998） 來羅西利(GB491)納入國家醫保藥品目錄 本公司董事會（「董事會」）宣佈，來羅西利(GB491)已納入由國家醫療保障局於 2025年12月7日發佈的《國家基本醫療保險、生育保險和工傷保險藥品目錄（2025 年）》（「國家醫保藥品目錄」）。此乃來羅西利(GB491)首次被納入國家醫保藥品目 錄。新版國家醫保藥品目錄將於2026年1月1日起生效。 GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （於開曼群島註冊成立的有限公司） 自願公告 嘉和生物藥業（開曼）控股有限公司 執行董事及首席財務官 翁承毅先生 香港，2025年12月8日 於本公告日期，董事會由六(6)名董事組成，即執行董事 ...

Core Viewpoint - The reverse acquisition of Jiahe Biotechnology-B by Yiteng Pharmaceutical marks a significant milestone as the first reverse merger of an unprofitable biotech company in the Hong Kong market, with the merger expected to be completed by December 30 [2][3]. Group 1: Merger Details - Yiteng Pharmaceutical will acquire Jiahe Biotechnology through a share swap, valuing Yiteng at $677 million and Jiahe at $197 million, resulting in Yiteng shareholders holding 77.43% and Jiahe shareholders 22.57% of the new entity [3]. - The new company will be named Yiteng Jiahe Pharmaceutical Group Limited, reflecting the merger of the two entities [2]. Group 2: Industry Context - The merger is seen as a "self-rescue" move for Jiahe Biotechnology, which has struggled with slow clinical progress and regulatory approvals, while Yiteng has faced challenges in its IPO attempts [4][6]. - The combination aims to leverage Jiahe's research capabilities and Yiteng's commercialization strengths, potentially creating a synergistic effect that enhances market competitiveness [7][9]. Group 3: Future Prospects - The merger is expected to accelerate the commercialization of Jiahe's product, GB491, and optimize its multi-specific antibody technology platform, while also establishing necessary commercial and regulatory capabilities [7][8]. - The transaction is viewed as a signal to the market regarding the value of mergers and acquisitions in the biotech sector, particularly for companies lacking stable cash flows [9].

Individual Company News - Li Auto (02015.HK) reported a total revenue of 25.9 billion yuan for Q1 2025, representing a year-on-year increase of 1.1%. Adjusted net profit was 1 billion yuan, down 20.5% year-on-year [1] - Sihuan Pharmaceutical (01093.HK) is in discussions with potential partners regarding licensing and collaboration in drug development, production, and commercialization [1] - SANY International (00631.HK) achieved a net profit of 636 million yuan in Q1, a year-on-year increase of 30.6%, driven by significant revenue growth in large port machinery, oil and gas equipment, silicon energy products, and overseas mining vehicle sales [1] - Minxin Group (00222.HK) has jointly established a partnership to invest in a national-level specialized and innovative technology enterprise [1] - China Orient Group (00581.HK) reported an operating profit of approximately 199 million yuan for Q1 after deducting financial costs [1] Pharmaceutical Sector News - Jiahe Biotech (06998.HK) received approval from the Chinese National Medical Products Administration for the market launch of the new drug GB491 [2] - Fosun Pharma (02196.HK) had its registration application for the drug Luwomeitini approved by the National Medical Products Administration [2] - Yum China (09987.HK) entered into a share repurchase agreement for a total buyback amount of approximately 510 million USD for the second half of the year [2]